Cover Image
市場調查報告書

Amgen Inc.的產品平台分析

Amgen Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253700
出版日期 內容資訊 英文 251 Pages
訂單完成後即時交付
價格
Back to Top
Amgen Inc.的產品平台分析 Amgen Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 251 Pages
簡介

Amgen Inc.ha是位於臨床階段的製藥公司。該公司致力於癌症和血管疾病等治療藥的藥物研發。

本報告提供Amgen Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Amgen Inc.的基本資料

Amgen Inc.概要

  • 主要資訊
  • 企業資料

Amgen Inc.:R&D概要

  • 主要的治療範圍

Amgen Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
  • 轉出授權產品

Amgen Inc.:開發中產品概況

  • 位於最終階段的開發中產品
  • 位於臨床實驗階段的開發中產品
  • 位於初期階段的開發中產品

Amgen Inc.:開發階段不明的開發中產品

Amgen Inc.:藥物簡介

Amgen Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各類型分子
  • 各作用機制

Amgen Inc.:最近的開發平台趨勢

Amgen Inc.:暫停中的計劃

Amgen Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介

Amgen Inc.:企業發表

Amgen Inc.:總公司和子公司的所在地

Amgen Inc.:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08002CDB

Summary

Global Markets Direct's, 'Amgen Inc. - Product Pipeline Review - 2016', provides an overview of the Amgen Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Amgen Inc.
  • The report provides overview of Amgen Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Amgen Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Amgen Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Amgen Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amgen Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amgen Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amgen Inc. Snapshot
    • Amgen Inc. Overview
    • Key Information
    • Key Facts
  • Amgen Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Amgen Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Amgen Inc. - Pipeline Products Glance
  • Amgen Inc. - Late Stage Pipeline Products
  • Amgen Inc. - Clinical Stage Pipeline Products
  • Amgen Inc. - Early Stage Pipeline Products
  • Amgen Inc. - Drug Profiles
    • adalimumab biosimilar
    • blinatumomab
    • darbepoetin alfa
    • denosumab
    • etanercept
    • etelcalcetide hydrochloride
    • romiplostim
    • AMG-334
    • bevacizumab biosimilar
    • evolocumab
    • fulranumab
    • panitumumab
    • rituximab biosimilar
    • romosozumab
    • trastuzumab biosimilar
    • trebananib
    • abrilumab
    • AMG-319
    • AMG-337
    • AMG-557
    • AMG-714
    • AMG-899
    • ganitumab
    • omecamtiv mecarbil MR
    • rilotumumab
    • tezepelumab
    • AMG-232
    • talimogene laherparepvec
    • AMG-172
    • AMG-208
    • AMG-211
    • AMG-224
    • AMG-228
    • AMG-282
    • AMG-301
    • AMG-330
    • AMG-357
    • AMG-581
    • AMG-592
    • AMG-595
    • AMG-780
    • AMG-811
    • AMG-820
    • AMG-876
    • AMG-900
    • AMG-XXX
    • infliximab biosimilar
    • pasotuxizumab
    • solitomab
    • AM-1638
    • AM-3189
    • AM-6226
    • AM-7209
    • AM-8553
    • AM-9514
    • AMG-0696
    • AMG-161
    • AMG-1694
    • AMG-176
    • AMG-3969
    • AMG-511
    • AMG-570
    • AMG-8718
    • AMG-986
    • Biosimilar 1 for Undisclosed Indication
    • Biosimilar 2 for Undisclosed Indication
    • Biosimilar 3 for Undisclosed Indication
    • Calcimimetic-18
    • cetuximab biosimilar
    • Drug for Atherosclerosis
    • Drugs to Inhibit FGF23 for Bone Disorders
    • Morpholinone-27
    • Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases
    • Recombinant Protein to Agonize FGFR for Type 2 Diabetes
    • Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes
    • Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes
    • Small Molecule to Agonize GPR119 for Undisclosed Indication
    • Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication
    • Small Molecule to Agonize GPR142 for Type 2 Diabetes
    • Small Molecule to Antagonize EP2 Receptor for Alzheimer Disease
    • Small Molecule to Inhibit BACE1 for Alzheimer's Disease
    • Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis
    • Small Molecule to Inhibit PI3K/mTOR for Cancer
    • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
    • Small Molecules to Inhibit BACE1 for Alzheimer Disease
    • Small Molecules to Inhibit PDE10A for Neurological Diseases
    • Small Molecules to Inhibit PI3K Delta for Inflammation
    • XmAb-13243
    • XmAb-13551
    • AA-71
    • Drugs for Inflammatory Bowel Disease
    • Monoclonal Antibodies for Cancer and Inflammation
    • Morpholinone-10
    • Morpholinone-16
    • Small Molecules to Inhibit CDC7 kinase for Cancer
    • Small Molecules to Inhibit IRAK-4 for Inflammation
    • Small Molecules to Inhibit NIK for Multiple Myeloma
    • Small Molecules to Inhibit Tankyrase for Cancer
  • Amgen Inc. - Pipeline Analysis
    • Amgen Inc. - Pipeline Products by Target
    • Amgen Inc. - Pipeline Products by Route of Administration
    • Amgen Inc. - Pipeline Products by Molecule Type
    • Amgen Inc. - Pipeline Products by Mechanism of Action
  • Amgen Inc. - Recent Pipeline Updates
  • Amgen Inc. - Dormant Projects
  • Amgen Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Amgen Inc. - Company Statement
  • Amgen Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Amgen Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amgen Inc., Key Information
  • Amgen Inc., Key Facts
  • Amgen Inc. - Pipeline by Indication, 2016
  • Amgen Inc. - Pipeline by Stage of Development, 2016
  • Amgen Inc. - Monotherapy Products in Pipeline, 2016
  • Amgen Inc. - Partnered Products in Pipeline, 2016
  • Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Amgen Inc. - Out-Licensed Products in Pipeline, 2016
  • Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Amgen Inc. - Pre-Registration, 2016
  • Amgen Inc. - Filing rejected/Withdrawn, 2016
  • Amgen Inc. - Phase III, 2016
  • Amgen Inc. - Phase II, 2016
  • Amgen Inc. - Phase I, 2016
  • Amgen Inc. - Preclinical, 2016
  • Amgen Inc. - Discovery, 2016
  • Amgen Inc. - Pipeline by Target, 2016
  • Amgen Inc. - Pipeline by Route of Administration, 2016
  • Amgen Inc. - Pipeline by Molecule Type, 2016
  • Amgen Inc. - Pipeline Products by Mechanism of Action, 2016
  • Amgen Inc. - Recent Pipeline Updates, 2016
  • Amgen Inc. - Dormant Developmental Projects,2016
  • Amgen Inc. - Discontinued Pipeline Products, 2016
  • Amgen Inc., Other Locations
  • Amgen Inc., Subsidiaries
  • Amgen Inc., Key Manufacturing Facilities

List of Figures

  • Amgen Inc. - Pipeline by Top 10 Indication, 2016
  • Amgen Inc. - Pipeline by Stage of Development, 2016
  • Amgen Inc. - Monotherapy Products in Pipeline, 2016
  • Amgen Inc. - Partnered Products in Pipeline, 2016
  • Amgen Inc. - Out-Licensed Products in Pipeline, 2016
  • Amgen Inc. - Pipeline by Top 10 Target, 2016
  • Amgen Inc. - Pipeline by Route of Administration, 2016
  • Amgen Inc. - Pipeline by Molecule Type, 2016
  • Amgen Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top